Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23971968 | 0.90 | HIF1A (0.41) | HIF1ANPC1RAB9A | |
| SCHEMBL23972105 | 0.89 | HIF1A (0.46) | HIF1A | |
| SCHEMBL23971901 | 0.88 | HIF1A (0.48) | HIF1AS1PR1S1PR3 | |
| SCHEMBL23971962 | 0.88 | HIF1A (0.42) | HIF1A | |
| SCHEMBL25599894 | 0.87 | HIF1A (0.47) | HIF1AS1PR1S1PR3 | |
| SCHEMBL23971891 | 0.86 | HIF1A (0.47) | HIF1APPARGPPARA | |
| SCHEMBL23971575 | 0.85 | HIF1A (0.59) | HIF1ANPC1RAB9APPARGPPARA | |
| SCHEMBL23972000 | 0.85 | HIF1A (0.53) | HIF1AS1PR1NPC1RAB9APPARG | |
| SCHEMBL23971656 | 0.84 | HIF1A (0.47) | HIF1AS1PR1S1PR3 | |
| SCHEMBL23971758 | 0.83 | HIF1A (0.52) | HIF1ANPC1RAB9APPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172205-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS IV | BASF SE (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230172205-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS IV | BASF SE (DE) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172205-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS IV | COX5B, SQOR, COX5A | HIF1A 2001/4885S1PR1 4802/4885S1PR3 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.